These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 23869534

  • 1. Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study.
    Lefebvre HP, Ollivier E, Atkins CE, Combes B, Concordet D, Kaltsatos V, Baduel L.
    J Vet Intern Med; 2013; 27(5):1083-91. PubMed ID: 23869534
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease.
    Bernay F, Bland JM, Häggström J, Baduel L, Combes B, Lopez A, Kaltsatos V.
    J Vet Intern Med; 2010; 24(2):331-41. PubMed ID: 20102506
    [Abstract] [Full Text] [Related]

  • 3. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
    Thomason JD, Rockwell JE, Fallaw TK, Calvert CA.
    J Vet Cardiol; 2007 Nov; 9(2):103-8. PubMed ID: 17983885
    [Abstract] [Full Text] [Related]

  • 4. Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs.
    Schuller S, Van Israël N, Vanbelle S, Clercx C, McEntee K.
    J Vet Pharmacol Ther; 2011 Aug; 34(4):322-31. PubMed ID: 20950346
    [Abstract] [Full Text] [Related]

  • 5. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y.
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [Abstract] [Full Text] [Related]

  • 6. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group.
    Ettinger SJ, Benitz AM, Ericsson GF, Cifelli S, Jernigan AD, Longhofer SL, Trimboli W, Hanson PD.
    J Am Vet Med Assoc; 1998 Dec 01; 213(11):1573-7. PubMed ID: 9838955
    [Abstract] [Full Text] [Related]

  • 7. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease.
    Ames MK, Atkins CE, Eriksson A, Hess AM.
    J Vet Cardiol; 2017 Jun 01; 19(3):218-227. PubMed ID: 28576479
    [Abstract] [Full Text] [Related]

  • 8. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K.
    J Vet Intern Med; 2013 Jun 01; 27(6):1452-62. PubMed ID: 24128373
    [Abstract] [Full Text] [Related]

  • 9. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST).
    Coffman M, Guillot E, Blondel T, Garelli-Paar C, Feng S, Heartsill S, Atkins CE.
    J Vet Intern Med; 2021 Jul 01; 35(4):1673-1687. PubMed ID: 34028078
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct 15; 78(8):902-7. PubMed ID: 8888663
    [Abstract] [Full Text] [Related]

  • 11. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
    Borgarelli M, Ferasin L, Lamb K, Bussadori C, Chiavegato D, D'Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall'Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.
    J Vet Cardiol; 2020 Feb 15; 27():34-53. PubMed ID: 32032923
    [Abstract] [Full Text] [Related]

  • 12. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J.
    N Engl J Med; 1999 Sep 02; 341(10):709-17. PubMed ID: 10471456
    [Abstract] [Full Text] [Related]

  • 13. The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy.
    James R, Guillot E, Garelli-Paar C, Huxley J, Grassi V, Cobb M.
    J Vet Cardiol; 2018 Feb 02; 20(1):1-12. PubMed ID: 29277469
    [Abstract] [Full Text] [Related]

  • 14. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2008 Feb 02; 22(5):1124-35. PubMed ID: 18638016
    [Abstract] [Full Text] [Related]

  • 15. Gingival hyperplasia associated with the administration of amlodipine to dogs with degenerative valvular disease (2004-2008).
    Thomason JD, Fallaw TL, Carmichael KP, Radlinsky MA, Calvert CA.
    J Vet Intern Med; 2009 Feb 02; 23(1):39-42. PubMed ID: 19175718
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation.
    Kvart C, Häggström J, Pedersen HD, Hansson K, Eriksson A, Järvinen AK, Tidholm A, Bsenko K, Ahlgren E, Ilves M, Ablad B, Falk T, Bjerkfås E, Gundler S, Lord P, Wegeland G, Adolfsson E, Corfitzen J.
    J Vet Intern Med; 2002 Feb 02; 16(1):80-8. PubMed ID: 11822810
    [Abstract] [Full Text] [Related]

  • 17. Clinical, echocardiographic, and neurohormonal effects of a sodium-restricted diet in dogs with heart failure.
    Rush JE, Freeman LM, Brown DJ, Brewer BP, Ross JN, Markwell PJ.
    J Vet Intern Med; 2000 Feb 02; 14(5):513-20. PubMed ID: 11012115
    [Abstract] [Full Text] [Related]

  • 18. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study.
    Hezzell MJ, Boswood A, López-Alvarez J, Lötter N, Elliott J.
    J Vet Cardiol; 2017 Aug 02; 19(4):325-338. PubMed ID: 28734620
    [Abstract] [Full Text] [Related]

  • 19. Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease.
    Peddle GD, Singletary GE, Reynolds CA, Trafny DJ, Machen MC, Oyama MA.
    J Vet Cardiol; 2012 Mar 02; 14(1):253-9. PubMed ID: 22364690
    [Abstract] [Full Text] [Related]

  • 20. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.
    O'Grady MR, Minors SL, O'Sullivan ML, Horne R.
    J Vet Intern Med; 2008 Mar 02; 22(4):897-904. PubMed ID: 18537880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.